
	Where results make sense

Topic: Fujisawa

Related Topics

Nagano, Nagano

Yamato, Kanagawa

Hirohisa Fujii

Kanagawa Prefecture

Nagano Prefecture

Enoshima

Sagami Bay

Katase River

Shonan

Japan

Clark University

Yuichiro Miura

Novo Nordisk

Pfizer

Abbott Laboratories

	Fujisawa, Kanagawa - Wikipedia, the free encyclopedia
		Fujisawa is located in central Kanagawa Prefecture, faces Sagami Bay of the Pacific Ocean,The northern part of the city is the Sagamino plateau, and the southern part is the Shonan Dunes.
		Fujisawa was mentioned in a document (Taiheiki) in the late 14th century.
		Fujisawa was a post town (宿場町 Shukuba-machi) of Tokaido during Edo period.
	en.wikipedia.org /wiki/Fujisawa (301 words)

	Tohru Fujisawa - Wikipedia, the free encyclopedia
		Tohru Fujisawa (藤沢とおる Fujisawa Tōru) is a Japanese manga author.
		His name is romanized as Tohru Fujisawa on the TOKYOPOP English-language Great Teacher Onizuka (GTO) books, while it is romanized as Toru Fujisawa on the Kodansha bilingual releases.
		Fujisawa's most well known work is * Great Teacher Onizuka, a 25-part series about a biker's attempts to become and remain a teacher.
	en.wikipedia.org /wiki/Tohru_Fujisawa (219 words)

	GoBase.org - Fujisawa Hideyuki - Biography
		Fujisawa Shuko, Born June 14, 1925 in Yokohama, Japan.
		Got expelled from the Nihon Kiin in 1999 because Fujisawa started to sell diploma's to amateurs by himself for a fee which is not in accordance with the fee charged by the Nihon Kiin.
		The point of this discrepancy is that Fujisawa reasons that the diploma fee is much too high, while the Nihon Kiin considers the diploma fee partly as a donation to their organisation.
	gobase.org /information/players/?pp=Fujisawa+Shuko (229 words)

	AEGiS-PRn: Roxane Acquires The Rights To Duraclon From Fujisawa
		Fujisawa USA developed Duraclon for the treatment of cancer pain and filed the NDA in the U.S. Roxane Laboratories will begin marketing Duraclon to anesthesiologists in January 1997.
		Fujisawa USA, Inc., headquartered in Deerfield, Ill., is a manufacturer of proprietary and multisource pharmaceutical products and a subsidiary of Fujisawa Pharmaceutical Co, Ltd., based in Osaka, Japan.
		Fujisawa Pharmaceutical, founded in 1894, is a leading pharmaceutical manufacturer and is actively developing its operations not only in Japan but on a global scale, particularly in North America, Europe and Asia.
	www.aegis.com /NEWS/PR/1996/pr961103.html (611 words)

	NetSci: The Biotech YellowPages - Fujisawa Pharmaceuticals (Site not responding. Last check: 2007-10-31)
		Founded in 1894, Fujisawa Pharmaceutical Co., Ltd. looks back on a history of over 100 years that have seen the Company develop into one of the leading pharmaceutical manufacturers in Japan.
		Fujisawa's commitment to R&D is central to the Company's mission to provide new, innovative products that contribute to the health and welfare of people all over the world.
		Fujisawa leads the Japanese pharmaceutical industry in the development of international operations.
	www.netsci.org /Resources/Biotech/Yellowpages/F/fujisawa.html (186 words)

	Miami Beach Sister Cities Program - Fujisawa, Japan
		The historic town of Fujisawa grew up as a temple town around Yugyoji Temple which was constructed in the 14th century.
		During the Edo period, Fujisawa prospered as one of the 53 staging posts along the Tokaido Highway which linked Edo (Tokyo) and Kyoto.
		Later on, Fujisawa became a thriving center of trade and commerce with an agricultural zone stretching out in the north, as well as a sightseeing and resort area.
	www.miamibeachsistercities.com /fujisawa.htm (279 words)

	Sensei's Library: Fujisawa Hosai
		Fujisawa was born in March 1919 in Yokohama.
		Unfortunately, he lost with a lopsided score of 2-7 and 1 jigo and was consequently forced down to a handicap of sen-ai-sen.
		As a result, Fujisawa was forced down to a handicap of josen (Black in every game), and the jubango was terminated early to avoid further embarrassment.
	senseis.xmp.net /?FujisawaHosai (301 words)

	Fujisawa travel guide - Wikitravel
		Fujisawa [1] is a small town near Kamakura, Japan.
		Most visitors arrive in Fujisawa via the Odakyu line from Shinjuku and Machida in Tokyo, or from Hakone to the west.
		This is a small, scenic train that connects Kamakura and Fujisawa.
	wikitravel.org /en/Fujisawa (313 words)

	Adherex.com: Fujisawa invests in Ottawa-based Adherex Technologies Investment enables biotech company to further ...
		"Fujisawa is a recognized leader in the pharmaceutical industry, and we are very pleased that they have chosen to invest in Adherex," said John Brooks, President and CEO of Adherex Technologies.
		About Fujisawa Pharmaceutical Co., Ltd. Founded in 1894, Fujisawa Pharmaceutical Co., Ltd. looks back on a history of over 100 years that have seen the company develop into one of the leading pharmaceutical manufacturers in Japan.
		Fujisawa's commitment to R&D; is central to the company's mission to provide new, innovative products that contribute to the health and welfare of people all over the world.
	www.adherex.com /news/news_items/2000-02-01 (552 words)

	BioSpace News for Fujisawa Healthcare (Site not responding. Last check: 2007-10-31)
		Fujisawa Healthcare, Inc. (FHI) and Gilead Sciences, Inc. (Nasdaq:GILD - news) today announced the publication of results of a multi-center head-to-head study comparing the use of AmBisome® (amphotericin B) liposome for injection to Abelcet® (amphotericin B) lipid complex in the empirical treatment of patients with febrile neutropenia.
		Fujisawa Healthcare announced today that the U.S. Food and Drug Administration (FDA) Dermatologic and Ophthalmic Advisory Committee found PROTOPIC (tacrolimus) ointment to be safe and effective for the treatment of moderate to severe atopic dermatitis, more commonly known as eczema.
		Fujisawa Canada, Inc. (Fujisawa) announced today that a New Drug Submission (NDS) for a new topical dermatology product was submitted to Canada's Therapeutic Products Program (TPP) on June 29, 2000.
	www.acor.org /drugs/pipeline/companies/news/179604.news.orig (933 words)

	FDA Warning Letter, Fujisawa Healthcare, Inc. (Protopic (tacrolimus 0.03% and 0.1%) Ointment)
		(Fujisawa) for Protopic that is in violation of the Federal Food, Drug and Cosmetic Act and applicable regulations.
		Made of a natural substance, this new treatment is steroid free.” This ad represents that Fujisawa developed a new kind of medicine for eczema that is made from a natural substance and is steroid free.
		Fujisawa makes the only new kind of medicine for eczema that has these characteristics.
	www.pharmcast.com /WarningLetters/Yr2001/Feb2001/Fujisawa0201.htm (324 words)

	HEMISPHERX BIOPHARMA SIGNS OPTION AGREEMENT FOR AMPLIGEN WITH FUJISAWA PHARMACEUTICAL COMPANY Company Receives ...
		Its European subsidiary, Fujisawa Deutschland Gmbh, is headquartered in Munich, Germany.
		CFS is defined by various governmental agencies as a serious debilitating disease in which patients suffer complex symptoms, including profoundly disabling fatigue, flu-like symptoms, headaches, sore throat, joint and muscle pain, mental fogginess, depression and sleep disorders.
		The Alferon® asset for overseas sales for a category of STD is currently being acquired by the Company as part of a multi-step purchase contract of inventory, intellectual property, commercial licenses and GMP approved facilities, which house the biological operations.
	www.hemispherx.net /content/investor/default.asp?goto=206 (759 words)

	globeandmail.com : globeinvestor.com : Cardiome and Fujisawa sign US$68 million partnership agreement
		Fujisawa Healthcare will be financially responsible for 75% of all future clinical development costs with Cardiome responsible for the remaining 25% of costs.
		Fujisawa Healthcare will be responsible for the development plan, NDA application and registration, along with the commercial manufacturing, marketing and sale of RSD1235.
		Fujisawa Pharmaceutical Co., Ltd., founded in 1894, is a leading pharmaceutical manufacturer with over 8,300 employees at international operations in North America, Europe, and Asia.
	www.globeinvestor.com /servlet/WireFeedRedirect?cf=GlobeInvestor/config&vg=BigAdVariableGenerator&date=20031016&archive=cnw&slug=1110161485 (1096 words)

	Fujisawa Healthcare, Inc. and Roche Partner to Expand Availability of Protopic
		Fujisawa Healthcare, Inc. is a subsidiary of Fujisawa Pharmaceutical Co., Ltd., based in Osaka, Japan.
		Fujisawa Pharmaceutical Co., Ltd., founded in 1894, is a leading pharmaceutical manufacturer and is actively developing its international operations in North America, Europe and Asia.
		Additional information on Fujisawa Healthcare, Inc. and its products can be found on the company's web site at http://www.fujisawa.com.
	www.prnewswire.com /cgi-bin/stories.pl?ACCT=104&STORY=/www/story/01-26-2004/0002095776&EDATE= (503 words)

	Absolute Anime / El-Hazard / Masamichi Fujisawa
		Fujisawa is a teacher at Makoto and Jinnai's school.
		This description came from Shayla, and was edited by yours truly (contact me).
		In TV it's just the same Fujisawa, except this time he's really in love with Miz, he's just not protecting her.
	www.absoluteanime.com /el-hazard/fujisawa.htm (205 words)

	Yoshiyuki Fujisawa (Site not responding. Last check: 2007-10-31)
		Fujisawa worked at the Industrial Bank of Japan, most recently as chairman of the board of directors, since March 2000.
		Fujisawa is a vice chairman of the Japan Association of Corporate Executives, serves as the vice chairman to the Security Analyst Association of Japan and the Japan Project Industry Council.
		Fujisawa serves as a board member to the Institute of International Finance and to the International Monetary Conference, and as a member of the International Monetary Fund, and Capital Markets Consultative Group.
	www.ml.com /about/org_structure_ml/fujisawa.htm (237 words)

	BioSpace News for Fujisawa Pharmaceutical (Site not responding. Last check: 2007-10-31)
		Fujisawa Pharmaceutical Co., Ltd., today announced that it would introduce a new human resources policy named "Job Challenge Policy" from October 1 this year.
		CVT-3146 is being developed to selectively increase coronary artery blood flow for the potential use as an adjunctive pharmacologic agent in cardiac perfusion imaging studies.
		In the longer term, however, increasing emphasis is placed on dose reduction or withdrawal of adjunctive immunosuppressants, with the aim to reduce the risks of over-immunosuppression and the number of side effects of therapy.
	www.acor.org /drugs/pipeline/companies/news/48704.news.orig (754 words)

	GlaxoSmithKline - Press Archive - Fujisawa Healthcare, Inc. and GlaxoSmithKline Consumer Healthcare agree to co-promote ...
		Protopic, currently marketed by Fujisawa, is the first in a new class of steroid-free prescription drugs called topical immunomodulators, or TIMs, to be developed in more than 40 years for the treatment of eczema.
		Fujisawa Healthcare, Inc., headquartered in Deerfield, Illinois, develops, manufactures and markets proprietary pharmaceutical products in the United States and abroad.
		Additional information on Fujisawa Healthcare, Inc. and its products can be found on the company's web site at www.fujisawa.com.
	www.gsk.com /press_archive/press2003/press_06042003.htm (445 words)

	Fujisawa and Roche to co-promote Mycamine - Pharmaceutical Business Review (Site not responding. Last check: 2007-10-31)
		Fujisawa Healthcare and Roche Pharmaceuticals have formed a partnership for the US co-promotion of Mycamine injection, Fujisawa's newly approved product for esophageal candidiasis and Candida infections.
		Mycamine (micafungin sodium), an antifungal in the echinocandin class, was approved by the FDA on March 16, 2005 for the treatment of patients with esophageal candidiasis and for the propylaxis of Candida infections in patients undergoing hematopoietic stem cell transplantation.
		Fujisawa will book sales and compensation to Roche will be based on product sales.
	www.pharmaceutical-business-review.com /article_news_print.asp?guid=2850D7E7-2FAF-4DF3-B99C-FBD3BD7E02EA (190 words)

	Gilead -- Canada Approves Antifungal Agent Ambisome®
		Fujisawa Canada plans to file a supplemental new drug submission to Health Canada that seeks approval of AmBisome for use as empirical therapy for presumed fungal infections in febrile, neutropenic patients and first-line therapy for Cryptococcal infections.
		In addition, Fujisawa Canada seeks a label expansion by providing Health Canada with comparative data demonstrating the superior safety profile of AmBisome compared to Abelcet in the treatment of empirical infections.
		Fujisawa Canada, Inc., headquartered in Markham, Ontario is a subsidiary of Fujisawa Healthcare, Inc., headquartered in Deerfield, IL.
	www.gilead.com /wt/sec/pr_953337254 (485 words)

	FUJISAWA Fact Sheet - Rx&D (Site not responding. Last check: 2007-10-31)
		Fujisawa Canada Inc based in Markham, Ontario is a research-based pharmaceutical company operating in Canada since 1991 as a subsidiary of Fujisawa Healthcare Inc of Deerfield, Illinois, the base of North American operations for the Fujisawa Pharmaceutical Co. Ltd.
		Fujisawa Canada Inc is a comprehensive pharmaceutical enterprise involved in clinical research and development as well as pharmaceutical sales and marketing with more than 40 full time employees.
		Currently, Fujisawa Canada Inc conducts clinical research and development in the areas of organ transplantation, systemic anti-fungal therapy and dermatology and also supports basic medical research at a number academic research institutions in Canada.
	www.canadapharma.org /Members/Fujisawa_e.htm (161 words)

	Fujisawa Healthcare, Inc. :: Mycamine(TM) Receives FDA Approval
		Fujisawa Healthcare, Inc., headquartered in Deerfield, Ill., develops, manufactures, and markets proprietary pharmaceutical products in the United States and abroad.
		Fujisawa Healthcare, Inc. established its presence in the anti-fungal market with the launch of AmBisome(R) (liposomal amphotericin B) in 1997.
		Additional information on Fujisawa Healthcare, Inc. and its products can be found on the Internet at http://www.fujisawa.com/.
	sev.prnewswire.com /medical-pharmaceuticals/20050317/CGW05917032005-1.html (518 words)

	Sensei's Library: Fujisawa Hideyuki
		Fujisawa Hideyuki (藤沢秀行, born 1925), commonly called Fujisawa Shuko (藤沢秀行 Fujisawa Shūkō), is a retired Japanese 9-dan Go professional.
		Fujisawa has a reputation for liking to drink and gamble.
		Fujisawa's name was originally Tamotsu, but he changed it to Hideyuki, which may also be pronounced Shuko.The character shu (秀, shū) is the same as the one in many Honinbo names, such as Shuwa, Shusaku, Shusai, Shuei.
	senseis.xmp.net /?FujisawaShuko (344 words)

	Akadot - Tohru Fujisawa (Site not responding. Last check: 2007-10-31)
		Calm, collected, and wearing his ultra-cool sunglasses, Fujisawa was accompanied by Toshihiro Miura, his editor at Kondansha Ltd. Publishers.
		Fujisawa gives Akadot the 411 on his high school background, inspiration for his popular manga series, and hopes for GTO in America.
		Tohru Fujisawa: The previous manga Syonan Jyunai Gumi was about a biker-gang, so I thought would be interesting to do the opposite of that.
	www.akadot.com /article.php?a=156&p=43 (732 words)

	Fujisawa Healthcare, Inc. Submits NDA for Treatment of Esophageal Candidiasis
		DEERFIELD, Ill., April 27 /PRNewswire/ -- Fujisawa Healthcare, Inc. (Fujisawa) announced today that a New Drug Application (NDA) has been submitted to the U.S. Food and Drug Administration (FDA) for their investigational antifungal product to be marketed in the U.S. under the name Mycamine(TM) (micafungin sodium).
		With the submission of the NDA, Fujisawa seeks approval of micafungin for the treatment of esophageal candidiasis.
		Treating the presence of candidiasis in the esophagus, before it moves past the gastrointestinal tract, is key in arresting the progress of the fungus before it reaches more difficult to treat areas such as the lungs, bloodstream and kidney.
	www.prnewswire.com /cgi-bin/stories.pl?ACCT=104&STORY=/www/story/04-27-2004/0002160489&EDATE= (332 words)

	FDA Warning Letter, Fujisawa Healthcare, Inc. (Prograf® (tacrolimus))
		The Division of Drug Marketing, Advertising, and Communications (DDMAC) has reviewed a journal advertisement (ad) for Prograf® (tacrolimus capsules and injection) by Fujisawa Healthcare, Inc. (Fujisawa) that appeared in the January 2004 issues of Transplantation and The Journal of Heart and Lung Transplantation.
		Moreover, the ad was not submitted to DDMAC at the time of initial dissemination, as required by 21 CFR 314.81(b)(3)(i).
		DDMAC requests that Fujisawa immediately cease the dissemination of violative promotional materials for Prograf such as those described above.
	www.pharmcast.com /WarningLetters/Yr2004/May2004/Fujisawa0504.htm (1155 words)

	Sensei's Library: Fujisawa Tesuji Dictionary
		Neither a dictionary nor limited to tesuji, this is the current standard work collecting and categorizing moves by function, not form, by Fujisawa Shuko.
		If you study a game and come to a point where you think that, say, a way of strengthening a base is called for, the Fujisawa book gives a long list of splendid examples.
		The Fujisawa is set up more like a dictionary in that there are sections, diagrams, and explanations, where about half the page is text.
	senseis.xmp.net /?FujisawaTesujiDictionary (2898 words)

	Fujisawa Symphony Orchestra (English) (Site not responding. Last check: 2007-10-31)
		Fujisawa Symphony Orchestra has contributed to the growth of culture in Fujisawa city by giving classical music concerts twice a year since its foundation in 1959.
		We are proud of playing an important role in performing Fujisawa Civic Opera, great pleasure for the residents, produced by Fujisawa City Culture Foundation every other year.
		Guided by the late Yoichiro Fukunaga, the orchestra's founder and conductor for 30 years, and by successive leaders of the orchestra, Fujisawa Symphony Orchestra was awarded Kanagawa Prefecture Culture Reward in 1995.
	orchestra.musicinfo.co.jp /~fujikyo/english.html (162 words)

Try your search on: Qwika (all wikis)